<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01862939</url>
  </required_header>
  <id_info>
    <org_study_id>DS7309-A-U101</org_study_id>
    <nct_id>NCT01862939</nct_id>
  </id_info>
  <brief_title>A Two-Part, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DS-7309 in Healthy Volunteers and Subjects With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Double Blind, Placebo-Controlled, Randomized, Two-Part, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DS-7309 in Healthy Volunteers and Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, placebo-controlled, 2-part, sequential, single ascending dose study.

      Part 1 is planned as 6 sequential escalation treatment groups. Part 2 is a randomized,
      placebo-controlled, two-period sequential pharmacodynamic (PD) arm.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incremental area under the curve (IAUC) blood glucose</measure>
    <time_frame>5 hours</time_frame>
    <description>The incremental area under the curve (IAUC) of the PD biomarker blood glucose following an oral glucose tolerance test (OGTT) in subjects with type 2 diabetes mellitus (T2DM).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>determine blood concentrations of DS-7309</measure>
    <time_frame>48 hours</time_frame>
    <description>The plasma pharmacokinetic (PK) parameters of A203-5319 (the free form of DS-7309) and relevant metabolite of DS-7309 in healthy subjects and subjects with T2DM.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>part 1 DS-7309 ascending dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1, 2.5, 5, 10, 20 mg blinded DS-7309 powder in bottle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>part 2 DS-7309</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1, 2.5, 5, and 15mg DS-7309 powder in bottle for oral solution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>part 2 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo to match part 2 DS-7309</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS-7309</intervention_name>
    <description>1, 2.5, 5, 10, 20 mg DS-7309 powder in bottle.</description>
    <arm_group_label>part 1 DS-7309 ascending dose</arm_group_label>
    <arm_group_label>part 2 DS-7309</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo to match part 2 DS-7309</description>
    <arm_group_label>part 2 placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women must be of non-child bearing potential, ie, either:

               1. Surgically sterile (ie, bilateral tubal ligation or removal of both ovaries
                  and/or uterus at least 6 months prior to dosing), or

               2. Naturally postmenopausal (spontaneous cessation of menses) for at least 24
                  consecutive months prior to dosing, with a follicle stimulating hormone (FSH)
                  level at screening of ≥ 40 mIU/mL.

          -  All women must have a negative serum pregnancy test at screening and within 48 hours
             before dosing.

          -  Able to understand and willing to comply with all study requirements, and willing to
             follow the study medication regimen.

          -  Subjects must give written informed consent to participation in the study prior to
             screening.

          -  Negative urine test for drugs of abuse and alcohol at screening and check-in.

          -  Negative result for HIV antibody, hepatitis B surface antigen, and hepatitis C
             antibody at screening.

          -  Subjects must agree to abstain from alcohol, cola, tea, coffee, chocolate and other
             caffeinated drink and food from 2 days before check-in and throughout confinement.

          -  Subjects must agree to abstain from grapefruit/grapefruit juice and Seville oranges
             from 10 days before the first dose and throughout the study.

          -  Healthy women who are not of childbearing potential and men, 18 to 45 years of age,
             inclusive.

          -  Body Mass Index (BMI) of 19.00 to 32.00 kg/m2 inclusive.

          -  Good health, as determined by the absence of clinically significant deviation from
             normal, based on medical history, physical examination, laboratory reports, and
             12-lead ECG, as deemed by the Investigator, prior to enrollment.

          -  Baseline (0 hour) pre-dose capillary blood glucose ≥ 70 mg/dL. Part 2 (T2DM subjects)

          -  Women who are not of childbearing potential and men, 18 to 55 years of age, inclusive.

          -  Diagnosis of type 2 diabetes mellitus for a minimum of 3 months prior to first dose.

          -  Body Mass Index (BMI) of 19.00 to 40.00 kg/m2 inclusive.

          -  Subjects should be either:

               1. Treatment naïve from any antidiabetic treatment for at least 6 months prior to
                  screening with a hemoglobin A1c (HBA1c) value between 7%-10%, inclusive.

               2. On metformin alone with a HBA1c value between 7%-9%, inclusive, and willing to
                  discontinue current metformin treatment for at least 2 weeks prior to study and
                  during the duration of the study. See Section 9.10.1 for monitoring during 2 week
                  washout.

        Exclusion Criteria:

          -  Female subject is of childbearing potential, is pregnant (as based on test results) or
             is breast feeding.

          -  Male subjects should ensure use of condom and spermicide from dosing until 12 weeks
             after dosing.

          -  Male subjects must agree not to donate sperm from dosing until 12 weeks after dosing.

          -  Any history of drug abuse.

          -  History of alcohol addiction during the 2 years prior to Day 1.

          -  History or current evidence, as determined by the Investigator, of psychiatric or
             emotional problems which would invalidate giving informed consent or limit the ability
             of the subject to comply with study requirements.

          -  History or current alcoholic or non-alcoholic liver disease or liver steatosis.

          -  History of neuropathy.

          -  Subjects with QTcF interval duration &gt;450 msec obtained from the ECG taken at
             screening, after at least 10 minutes of quiet rest in a supine position.

          -  Subjects with a family history of long QT syndrome.

          -  Subjects with any history of arrhythmia.

          -  Significant blood donation or significant blood loss within the 56 days before Day -1.

          -  Plasma donation within 7 days before Day -1.

          -  Participation in another investigational new drug research study within the 30 days
             before Day 1.

          -  Use of tobacco products or nicotine-containing products (including smoking cessation
             aids, such as gums or patches) within the 6 months before Day 1.

          -  Relationship of the subject to the Investigator, any sub-investigator, pharmacist,
             study coordinator, or other staff directly involved in the conduct of the study, or
             employment by the Sponsor or contract research organization participating in the
             study.

          -  Familial relationship of the subject to any subjects previously or currently enrolled
             in the study.

          -  Screening laboratory values outside the range of normal values that are deemed
             clinically significant by the Investigator. Liver function tests (AST, ALT, total
             bilirubin, and lactate dehydrogenase [LDH]) must be at or below the ULN. If a subject
             has a non-clinically significant high abnormal reading for one or more of the liver
             function tests on the screening lab test, the test may be repeated once. If the lab
             test results are normal on the repeat test, he/she may be enrolled provided the Day -1
             lab test results are also normal.

          -  Hemoglobin levels below the lower limit of normal of the clinical laboratory's
             reference range at the screening visit.

          -  Enrollment in a prior dose cohort of this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2013</study_first_submitted>
  <study_first_submitted_qc>May 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2013</study_first_posted>
  <last_update_submitted>May 24, 2013</last_update_submitted>
  <last_update_submitted_qc>May 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type 2 diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

